Servier, shared on LinkedIn:
“With nearly one-third of its population aged 65+, Japan faces a growing cancer burden – making access to innovative therapies more critical than ever.
Almost 1 million new cancer cases and close to 400,000 cancer-related deaths are expected annually, reinforcing oncology as a key public health priority.
Combining a rapidly aging population, strong demand for innovative treatments and a healthcare system that supports rapid access to medical innovation, the country offers a unique environment to accelerate the development and availability of precision therapies for patients living with cancer.
At Servier, we are proud to be part of this journey:
- Over 40 years of presence in Japan
- Local clinical development across all phases
- Direct commercialization of oncology therapies since 2020
- Continued expansion to better serve patients with rare cancers
Other articles about Servier on OncoDaily.